OmniAb Inc.
$ 1.93
-1.53%
26 Dec - close price
- Market Cap 277,834,000 USD
- Current Price $ 1.93
- High / Low $ 1.94 / 1.85
- Stock P/E N/A
- Book Value 1.93
- EPS -0.59
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.13 %
- ROE -0.22 %
- 52 Week High 4.02
- 52 Week Low 1.22
About
None
Analyst Target Price
$7.33
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-03-18 | 2024-11-12 | 2024-08-08 | 2024-05-09 | 2024-03-20 | 2023-11-09 | 2023-08-10 | 2023-05-11 | 2023-03-30 |
| Reported EPS | -0.14 | -0.15 | -0.17 | -0.12 | -0.16 | -0.13 | -0.19 | -0.14 | -0.16 | -0.15 | -0.08 | 0.07 |
| Estimated EPS | -0.136 | -0.13 | -0.1667 | -0.0967 | -0.14 | -0.17 | -0.16 | -0.15 | -0.14 | -0.12 | -0.03 | 0.02 |
| Surprise | -0.004 | -0.02 | -0.0033 | -0.0233 | -0.02 | 0.04 | -0.03 | 0.01 | -0.02 | -0.03 | -0.05 | 0.05 |
| Surprise Percentage | -2.9412% | -15.3846% | -1.9796% | -24.0951% | -14.2857% | 23.5294% | -18.75% | 6.6667% | -14.2857% | -25% | -166.6667% | 250% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OABI
2025-12-16 14:09:03
Two analysts have issued bullish sentiments on healthcare companies Novan (NOVN) and OmniAb (OABI). While the article mentions Novan, it only provides details for OmniAb, where analyst Matt Hewitt from Craig-Hallum maintained a Buy rating, noting a consensus of Strong Buy with a $6.75 price target.
2025-12-16 11:09:38
OmniAb, Inc. (NASDAQ: OABI) has launched its new OmniUltra™ platform, the first transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework, at the 2025 Antibody Engineering & Therapeutics Conference. This innovative platform broadens therapeutic opportunities beyond conventional antibodies and introduces picobodies™, the smallest known natural antibody-derived binding domain. OmniUltra is designed to deliver pre-optimized specificity, affinity, and structural stability for various applications, reinforcing OmniAb's leadership in drug discovery innovation.
2025-12-16 09:09:10
OmniAb, Inc. has launched its new OmniUltra™ platform, the industry's first transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework. This platform broadens therapeutic opportunities beyond conventional antibodies, enabling the discovery of novel binding modes and access to challenging targets, and facilitating applications in areas like bispecifics, multispecifics, CAR-T, and stand-alone peptide therapeutics. OmniUltra also allows for the isolation of picobodies™, the smallest natural antibody-derived binding domains, and represents a pioneering advancement in antibody and peptide discovery.
2025-12-14 12:09:10
OmniAb (NASDAQ: OABI) insiders who invested US$1.59 million in the last year have seen their holdings appreciate by US$277,000, thanks to a 10% stock gain. This included a significant US$1 million purchase by President Matthew Foehr at a price below the current market value, suggesting insiders see value in the company. Overall, insiders bought more shares than they sold, and their collective ownership stands at 12%, aligning their interests with other shareholders.
2025-12-13 13:09:05
Insiders at OmniAb, Inc. have seen a significant appreciation of US$277k on their US$1.59m investment over the last 12 months, largely due to a 10% stock gain. While individual transactions vary, there has been more insider buying than selling, indicating confidence in the company, despite it currently incurring losses. Insiders own 12% of the company, suggesting good alignment with shareholders.
2025-12-13 11:09:38
Insiders at OmniAb, Inc. (NASDAQ:OABI) have seen a US$277k appreciation on their US$1.59m investment over the last year, coinciding with a 10% increase in the company's market value. While one significant purchase was made below the current price, overall insider buying exceeded selling, indicating confidence in the company's future despite current losses. Insiders collectively own 12% of OmniAb, aligning their interests with other shareholders.
